Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 7/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6482473 | 1.00 | TSHR (0.56) | TSHRALDH1A1LMNAALOX12SMN1; SMN2 | |
| SCHEMBL1120426 | 1.00 | TSHR (0.56) | TSHRALDH1A1LMNAALOX12SMN1; SMN2 | |
| SCHEMBL10684124 | 0.97 | TSHR (0.54) | TSHRALDH1A1LMNAALOX12SMN1; SMN2 | |
| SCHEMBL10684133 | 0.97 | TSHR (0.54) | TSHRALDH1A1LMNAALOX12SMN1; SMN2 | |
| SCHEMBL12841102 | 0.93 | TSHR (0.50) | TSHRALDH1A1LMNAALOX12SMN1; SMN2 | |
| SCHEMBL13839948 | 0.87 | TSHR (0.45) | TSHRALDH1A1LMNAALOX12SMN1; SMN2 | |
| SCHEMBL46155 | 0.86 | TSHR (0.72) | TSHRCHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL10689902 | 0.84 | CHRM2 (0.42) | TSHRALDH1A1LMNAALOX12SMN1; SMN2 | |
| SCHEMBL10688813 | 0.84 | TSHR (0.42) | TSHRALDH1A1LMNAALOX12SMN1; SMN2 | |
| SCHEMBL10688802 | 0.84 | TSHR (0.42) | TSHRALDH1A1LMNAALOX12SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115927276-B | Halohydrin dehalogenase mutant and application thereof in synthesis of chiral oxazolidinone | 中国科学院天津工业生物技术研究所 | 2024-08-27 | — | — | CN | claimed |
| CN-115927276-B | Halohydrin dehalogenase mutant and application thereof in synthesis of chiral oxazolidinone | 中国科学院天津工业生物技术研究所 | 2024-08-27 | — | — | CN | disclosed |
| CN-115927276-A | Halogen alcohol dehalogenase mutant and application thereof in synthesizing chiral oxazolidinone | 中国科学院天津工业生物技术研究所 | 2023-04-07 | — | — | CN | disclosed |
| US-9012452-B2 | Processes for making cyclopropyl amide derivatives and intermediates associated therewith | ASTRAZENECA AB (SE) | 2015-04-21 | — | — | US | disclosed |
| US-8623873-B2 | Substituted piperazines as CB1 antagonists | INTERVET INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8623873-B2 | Substituted piperazines as CB1 antagonists | INTERVET INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-20130172560-A1 | PROCESSES FOR MAKING CYCLOPROPYL AMIDE DERIVATIVES AND INTERMEDIATES ASSOCIATED THEREWITH | ASTRAZENECA AB (SE) | 2013-07-04 | — | — | US | disclosed |
| EP-2548874-A2 | Substituted piperazines as CB1 antagonists | Intervet International B.V. (NL) | 2013-01-23 | — | — | EP | disclosed |
| US-20090105208-A1 | Substituted Piperazines as CB1 Antagonists | SCHERING CORPORATION | 2009-04-23 | — | — | US | disclosed |
| US-20090105208-A1 | Substituted Piperazines as CB1 Antagonists | SCHERING CORPORATION | 2009-04-23 | — | — | US | disclosed |
| WO-2009005646-A2 | SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS | SCHERING CORPORATION (US) | 2009-01-08 | — | — | WO | disclosed |
| US-20050090669-A1 | Aminoalcohol derivatives as beta-3 adrenergic receptor agonists | ASTELLAS PHARMA INC. (JP) | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172560-A1 | PROCESSES FOR MAKING CYCLOPROPYL AMIDE DERIVATIVES AND INTERMEDIATES ASSOCIATED THEREWITH | HRH4, HRH2, HRH3 | TSHR 419/4885ALDH1A1 398/4885LMNA 4847/4885 |
| US-20090105208-A1 | Substituted Piperazines as CB1 Antagonists | CNR1, CNR2, GPR119 | TSHR 913/4885ALDH1A1 1520/4885LMNA 4038/4885 |
| US-20050090669-A1 | Aminoalcohol derivatives as beta-3 adrenergic receptor agonists | ADRB2, ADRB1, ADRB3 | TSHR 1056/4885ALDH1A1 664/4885LMNA 2444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.